Literature DB >> 11333140

Veto activity of activated bone marrow does not require perforin and Fas ligand.

P Chrobak1, R E Gress.   

Abstract

Veto cells suppress generation of CD8(+) T cell immune responses in an antigen-specific manner, with specificity dictated by antigens on the veto cell surface. Activated bone marrow (ABM) veto cells belong to the NK cell type lineage and veto by clonally deleting antigen-specific precursor cytotoxic T cell lymphocyte (CTL). In vitro cytotoxicity of ABM depends largely on the perforin/granzyme and Fas/Fas ligand pathways. Utilizing perforin-deficient and functional Fas ligand-deficient gld mice as a source of ABM and functional Fas-deficient lpr mice as a source of precursor CTL, we demonstrate in this study that ABM cells utilize a perforin- and Fas-independent pathway to veto allogeneic cell-mediated cytotoxic responses. We also show that ABM cells mediate perforin- and Fas-independent veto activity even in an 8-h clonal deletion assay. We conclude that ABM veto activity does not require the two primary pathways of cell-mediated death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333140     DOI: 10.1006/cimm.2001.1771

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Authors:  Sanja Vodanovic-Jankovic; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

3.  The use of donor-derived veto cells in hematopoietic stem cell transplantation.

Authors:  Eran Ophir; Yair Reisner
Journal:  Front Immunol       Date:  2012-05-02       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.